CardioDx to Present at the 12th Annual Needham Healthcare Conference
PALO ALTO, Calif., April 23, 2013 /PRNewswire/ — CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 9:40 AM ET at the Westin Grand Central Hotel in New York. David Levison, the company’s President and Chief Executive Officer, will provide an overview of CardioDx and Corus(®) CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD).
CardioDx recently announced the publication of the COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) study in Circulation: Cardiovascular Genetics, a journal of the American Heart Association. Results of the prospective, multi-center U.S. study showed that Corus CAD outperformed traditional stress testing with myocardial perfusion imaging (MPI), demonstrating high accuracy with both a higher sensitivity (89 percent vs. 27 percent) and higher negative predictive value (96 percent vs. 88 percent) than MPI for assessing the presence of obstructive CAD.
With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient’s symptoms are due to obstructive CAD, enabling many patients to avoid unnecessary noninvasive and invasive cardiac procedures and exposure to imaging-related radiation risks or imaging agent intolerance. Corus CAD is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has been used commercially by clinicians in more than 35,000 patients and is a covered benefit for more than 40 million Medicare enrollees in the U.S.
Corus CAD has been recognized by The Wall Street Journal‘s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME‘s Top Ten Medical Breakthroughs. CardioDx was recently honored as one of FierceMedicalDevices‘ “Fierce 15″ most promising privately-held medical device and diagnostic companies.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.
This press release may contain forward-looking statements, including statements regarding the efficacy and size of the market for Corus CAD. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These statements reflect the views of CardioDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
SOURCE CardioDx, Inc.